» Articles » PMID: 6087160

DARPP-32, a Dopamine-regulated Neuronal Phosphoprotein, is a Potent Inhibitor of Protein Phosphatase-1

Overview
Journal Nature
Specialty Science
Date 1984 Aug 9
PMID 6087160
Citations 189
Authors
Affiliations
Soon will be listed here.
Abstract

The neurotransmitter dopamine has been demonstrated by biochemical, histochemical and immunocytochemical techniques to be unevenly distributed in the mammalian central nervous system. DARPP-32 (dopamine- and cyclic-AMP-regulated phosphoprotein of molecular weight 32,000) is a neuronal phosphoprotein that displays a regional distribution in the mammalian brain very similar to that of dopamine-containing nerve terminals, being highly concentrated in the basal ganglia. The state of phosphorylation of DARPP-32 can be regulated by dopamine and by cyclic AMP in intact nerve cells, suggesting a role for this phosphoprotein in mediating certain of the effects of dopamine on dopaminoceptive cells. The observation that many of the physical and chemical properties of purified DARPP-32 resemble those of phosphatase inhibitor-1 (inhibitor-1), a widely distributed inhibitor of protein phosphatase-1, suggests that DARPP-32 might also function as a phosphatase inhibitor. We report here that DARPP-32 inhibits protein phosphatase-1 at nanomolar concentrations. Moreover, like inhibitor-1, DARPP-32 is effective as an inhibitor in its phosphorylated but not its dephosphorylated form. Thus, the basal ganglia of mammalian brain contain a region-specific neuronal phosphoprotein that is a protein phosphatase inhibitor.

Citing Articles

Cannabinoid regulation of angiotensin II-induced calcium signaling in striatal neurons.

Rivas-Santisteban R, Munoz A, Lillo J, Raich I, Rodriguez-Perez A, Navarro G NPJ Parkinsons Dis. 2024; 10(1):220.

PMID: 39548112 PMC: 11568119. DOI: 10.1038/s41531-024-00827-7.


Exploring the Role of DARPP-32 in Addiction: A Review of the Current Limitations of Addiction Treatment Pathways and the Role of DARPP-32 to Improve Them.

Greener M, Storr S NeuroSci. 2024; 3(3):494-509.

PMID: 39483434 PMC: 11523713. DOI: 10.3390/neurosci3030035.


Dopamine and cyclic adenosine monophosphate-regulated phosphoprotein with an apparent Mr of 32000 promotes colorectal cancer growth.

He K, Xie C, Li Y, Chen Z, Xu S, Huang S World J Gastrointest Oncol. 2023; 15(11):1936-1950.

PMID: 38077650 PMC: 10701231. DOI: 10.4251/wjgo.v15.i11.1936.


Unravelling transcriptomic complexity in breast cancer through modulation of DARPP-32 expression and signalling pathways.

Saidy B, Vasan R, Durant R, Greener M, Immanuel A, Green A Sci Rep. 2023; 13(1):21163.

PMID: 38036593 PMC: 10689788. DOI: 10.1038/s41598-023-48198-y.


Phosphodiesterase-4 Inhibition in Parkinson's Disease: Molecular Insights and Therapeutic Potential.

Roy D, Balasubramanian S, Krishnamurthy P, Sola P, Rymbai E Cell Mol Neurobiol. 2023; 43(6):2713-2741.

PMID: 37074485 PMC: 11410141. DOI: 10.1007/s10571-023-01349-1.